GeoVax Labs (GOVX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

GOVX Stock Forecast

GeoVax Labs stock forecast is as follows: an average price target of $4.00 (represents a 74.67% upside from GOVX’s last price of $2.29) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

GOVX Price Target

The average price target for GeoVax Labs (GOVX) is $4.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $4.00. This represents a potential 74.67% upside from GOVX's last price of $2.29.

GOVX Analyst Ratings

Buy

According to 4 Wall Street analysts, GeoVax Labs's rating consensus is 'Buy'. The analyst rating breakdown for GOVX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

GeoVax Labs Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jul 02, 2024	Vernon Bernardino	H.C. Wainwright	$4.00	$1.64	143.90%	74.67%

The latest GeoVax Labs stock forecast, released on Jul 02, 2024 by Vernon Bernardino from H.C. Wainwright, set a price target of $4.00, which represents a 143.90% increase from the stock price at the time of the forecast ($1.64), and a 74.67% increase from GOVX last price ($2.29).

GeoVax Labs Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$4.00
Last Closing Price	$2.29	$2.29	$2.29
Upside/Downside	-100.00%	-100.00%	74.67%

In the current month, the average price target of GeoVax Labs stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to GeoVax Labs's last price of $2.29. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 19, 2024	Noble Capital Markets	Outperform	Outperform	Hold
Jul 23, 2024	EF Hutton		Buy	Initialise
Jun 18, 2024	H.C. Wainwright	Buy	Buy	Hold
May 24, 2022	Maxim Group	Buy	Buy	Hold

GeoVax Labs's last stock rating was published by Noble Capital Markets on Aug 19, 2024. The company gave GOVX a "Outperform" rating, the same as its previous rate.

GeoVax Labs Financial Forecast

GeoVax Labs Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 20	Dec 19	Sep 19	Jun 19	Sep 12
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$251.62K	$268.51K	$333.21K	$209.94K	$638.00K
Avg Forecast	$41.70M	$37.23M	$35.75M	$34.26M	$514.37M	$12.83M	$12.32M	$11.80M	$2.38M	$2.30M	$2.30M	$2.25M	$2.38M	$1.33M	$300.68K	$400.00K	$300.00K	$300.00K	$300.00K	$638.00K
High Forecast	$44.48M	$39.72M	$38.13M	$36.54M	$548.66M	$13.69M	$13.14M	$12.59M	$2.53M	$2.45M	$2.45M	$2.40M	$2.48M	$1.42M	$300.68K	$400.00K	$300.00K	$300.00K	$300.00K	$765.60K
Low Forecast	$38.92M	$34.75M	$33.36M	$31.97M	$480.08M	$11.97M	$11.50M	$11.02M	$2.22M	$2.15M	$2.15M	$2.10M	$2.24M	$1.25M	$300.68K	$400.00K	$300.00K	$300.00K	$300.00K	$510.40K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	4	2	1	1	1	1	1	13
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.63%	0.90%	1.11%	0.70%	1.00%

GeoVax Labs's average Quarter revenue forecast for Jun 24 based on 1 analysts is $300.68K, with a low forecast of $300.68K, and a high forecast of $300.68K. GOVX's average Quarter revenue forecast represents a 19.50% increase compared to the company's last Quarter revenue of $251.62K (Dec 20).

GeoVax Labs EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 20	Dec 19	Sep 19	Jun 19	Sep 12
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	4	2	1	1	1	1	1	13
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-1.32M	$-586.72K	$-421.48K	$-651.16K	$-273.37K
Avg Forecast	$-25.02M	$-22.34M	$-21.45M	$-20.55M	$-308.62M	$-7.70M	$-7.39M	$-7.08M	$-1.43M	$-1.38M	$-1.38M	$-1.35M	$-1.43M	$-801.00K	$-180.41K	$-240.00K	$-180.00K	$-180.00K	$-631.22K	$-364.49K
High Forecast	$-23.35M	$-20.85M	$-20.02M	$-19.18M	$-288.05M	$-7.18M	$-6.90M	$-6.61M	$-1.33M	$-1.29M	$-1.29M	$-1.26M	$-1.35M	$-747.60K	$-180.41K	$-240.00K	$-180.00K	$-180.00K	$-504.98K	$-291.59K
Low Forecast	$-26.69M	$-23.83M	$-22.88M	$-21.92M	$-329.20M	$-8.21M	$-7.88M	$-7.55M	$-1.52M	$-1.47M	$-1.47M	$-1.44M	$-1.49M	$-854.40K	$-180.41K	$-240.00K	$-180.00K	$-180.00K	$-757.47K	$-437.39K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.50%	3.26%	2.34%	1.03%	0.75%

undefined analysts predict GOVX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than GeoVax Labs's previous annual EBITDA (undefined) of $NaN.

GeoVax Labs Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 20	Dec 19	Sep 19	Jun 19	Sep 12
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	4	2	1	1	1	1	1	13
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-1.34M	$-590.59K	$-424.43K	$-654.15K	$-296.78K
Avg Forecast	-	-	-	-	-	-	-	-	$-2.60M	$-2.54M	$-2.95M	$-2.99M	$-4.92M	$-8.43M	$-8.55M	$-1.52M	$-792.44B	$-1.23T	$-634.12K	$-395.70K
High Forecast	-	-	-	-	-	-	-	-	$-2.38M	$-2.32M	$-2.69M	$-2.69M	$-3.74M	$-7.70M	$-8.55M	$-1.52M	$-792.44B	$-1.23T	$-507.30K	$-316.56K
Low Forecast	-	-	-	-	-	-	-	-	$-2.83M	$-2.76M	$-3.20M	$-3.21M	$-6.23M	$-9.16M	$-8.55M	$-1.52M	$-792.44B	$-1.23T	$-760.95K	$-474.85K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.88%	0.00%	0.00%	1.03%	0.75%

GeoVax Labs's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GOVX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

GeoVax Labs SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 20	Dec 19	Sep 19	Jun 19	Sep 12
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	4	2	1	1	1	1	1	13
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$831.36K	$423.49K	$291.48K	$412.65K	$334.17K
Avg Forecast	$621.01M	$554.47M	$532.29M	$510.11M	$7.66B	$191.05M	$183.41M	$175.77M	$35.37M	$34.25M	$34.25M	$33.51M	$35.44M	$19.88M	$4.48M	$5.96M	$4.47M	$4.47M	$4.47M	$445.55K
High Forecast	$662.41M	$591.44M	$567.78M	$544.12M	$8.17B	$203.79M	$195.64M	$187.49M	$37.72M	$36.53M	$36.53M	$35.74M	$36.99M	$21.21M	$4.48M	$5.96M	$4.47M	$4.47M	$4.47M	$534.66K
Low Forecast	$579.61M	$517.51M	$496.81M	$476.11M	$7.15B	$178.32M	$171.18M	$164.05M	$33.01M	$31.97M	$31.97M	$31.27M	$33.41M	$18.55M	$4.48M	$5.96M	$4.47M	$4.47M	$4.47M	$356.44K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.14%	0.09%	0.07%	0.09%	0.75%

GeoVax Labs's average Quarter SG&A projection for Jun 24 is $4.48M, based on 1 Wall Street analysts, with a range of $4.48M to $4.48M. The forecast indicates a 438.57% rise compared to GOVX last annual SG&A of $831.36K (Dec 20).

GeoVax Labs EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 20	Dec 19	Sep 19	Jun 19	Sep 12
# Analysts	1	1	1	1	1	1	1	1	1	1	1	2	4	2	1	1	1	1	1	13
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.25	$-2.52	$-177.59	$-32.71K	$-0.43
Avg Forecast	-	-	-	-	-	-	-	-	$-0.41	$-0.40	$-0.46	$-0.47	$-0.77	$-1.32	$-3.37	$-0.60	$-312.00K	$-486.00K	$-588.00K	$-40.00K
High Forecast	-	-	-	-	-	-	-	-	$-0.37	$-0.36	$-0.42	$-0.42	$-0.58	$-1.20	$-3.37	$-0.60	$-312.00K	$-486.00K	$-588.00K	$-32.00K
Low Forecast	-	-	-	-	-	-	-	-	$-0.44	$-0.43	$-0.50	$-0.50	$-0.97	$-1.43	$-3.37	$-0.60	$-312.00K	$-486.00K	$-588.00K	$-48.00K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.42%	0.00%	0.00%	0.06%	0.00%

According to undefined Wall Street analysts, GeoVax Labs's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GOVX previous annual EPS of $NaN (undefined).

GeoVax Labs Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ATXI	Avenue Therapeutics	$1.66	$12.00	622.89%	Buy
OCGN	Ocugen	$0.83	$5.00	502.41%	Buy
ZURA	Zura Bio	$2.51	$10.00	298.41%	Buy
GOVX	GeoVax Labs	$2.27	$4.00	76.21%	Buy

GOVX Forecast FAQ

Is GeoVax Labs a good buy?

Yes, according to 4 Wall Street analysts, GeoVax Labs (GOVX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of GOVX's total ratings.

What is GOVX's price target?

GeoVax Labs (GOVX) average price target is $4 with a range of $4 to $4, implying a 74.67% from its last price of $2.29. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will GeoVax Labs stock go up soon?

According to Wall Street analysts' prediction for GOVX stock, the company can go up by 74.67% (from the last price of $2.29 to the average price target of $4), up by 74.67% based on the highest stock price target, and up by 74.67% based on the lowest stock price target.

Can GeoVax Labs stock reach $3?

GOVX's average twelve months analyst stock price target of $4 supports the claim that GeoVax Labs can reach $3 in the near future.

What are GeoVax Labs's analysts' financial forecasts?

GeoVax Labs's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $551.32M (high $588.07M, low $514.57M), average EBITDA is $-331M (high $-309M, low $-353M), average net income is $0 (high $0, low $0), average SG&A $8.21B (high $8.76B, low $7.66B), and average EPS is $0 (high $0, low $0). GOVX's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $148.94M (high $158.87M, low $139.01M), average EBITDA is $-89.363M (high $-83.406M, low $-95.321M), average net income is $0 (high $0, low $0), average SG&A $2.22B (high $2.37B, low $2.07B), and average EPS is $0 (high $0, low $0).

Did the GOVX's actual financial results beat the analysts' financial forecasts?

Based on GeoVax Labs's last annual report (Dec 2020), the company's revenue was $1.82M, beating the average analysts forecast of $400K by 355.75%. Apple's EBITDA was $-2.817M, beating the average prediction of $-240K by 1073.75%. The company's net income was $-2.936M, beating the average estimation of $-1.524M by 92.65%. Apple's SG&A was $2.2M, missing the average forecast of $5.96M by -63.13%. Lastly, the company's EPS was $-2.12, beating the average prediction of $-0.6 by 253.33%. In terms of the last quarterly report (Dec 2020), GeoVax Labs's revenue was $251.62K, missing the average analysts' forecast of $400K by -37.09%. The company's EBITDA was $-1.319M, beating the average prediction of $-240K by 449.60%. GeoVax Labs's net income was $-1.337M, missing the average estimation of $-1.524M by -12.30%. The company's SG&A was $831.36K, missing the average forecast of $5.96M by -86.04%. Lastly, the company's EPS was $-0.251, missing the average prediction of $-0.6 by -58.22%